Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mammarenavirus lassaense

ABSTRACT: Lassa virus patient sequencing

PROVIDER: PRJNA436552 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24390000_1.fastq.gz	Fastqsanger.gz
	SRR24390000_2.fastq.gz	Fastqsanger.gz
	SRR24390001_1.fastq.gz	Fastqsanger.gz
	SRR24390001_2.fastq.gz	Fastqsanger.gz
	SRR24363102_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 516

Similar Datasets

Mammarenavirus lassaense

Project description:Lassa Virus Sequencing

| PRJNA482054 | ENA

Mammarenavirus lassaense

Project description:Lassa virus overview

| PRJNA73833 | ENA

Mammarenavirus lassaense

Project description:Lassa mammarenavirus MinION Sequencing

| PRJNA482058 | ENA

Mammarenavirus lassaense

Project description:Genomic characterization of clinical Lassa virus isolates from 2017-2023 transmission seasons in Sierra Leone

| PRJNA962841 | ENA

Mammarenavirus lassaense

Project description:Genomic characterization of clinical Lassa virus isolates from 2017-2023 transmission seasons in Sierra Leone

| PRJNA962938 | ENA

Mammarenavirus lassaense isolate:Lassa virus

Project description:Genomic characterization of clinical Lassa virus isolates from 2017-2023 transmission seasons in Sierra Leone

| PRJNA966213 | ENA

Mammarenavirus lassaense

Project description:Mammarenavirus lassaense Genome sequencing

| PRJNA254017 | ENA

Mammarenavirus lassaense

Project description:Mammarenavirus lassaense Genome sequencing

| PRJNA428357 | ENA

Mammarenavirus lassaense strain:Mopeia-Lassa 29

Project description:Assessing the variation of an attenuated Lassa vaccine after passage in vivo

| PRJNA73681 | ENA

Transcriptome Analysis of Human Peripheral Blood Mononuclear Cells Exposed to Lassa Virus and to the Reassortant ML29, a Vaccine Candidate

Project description:The virulent Lassa fever virus (LASV) and the non-pathogenic Mopeia virus (MOPV) infect rodents and incidentally people in West Africa. The mechanism of LASV damage in human beings is unclear. A live-attenuated reassortant of MOPV and LASV protects rodents and primates from Lassa fever disease. Peripheral blood mononuclear cells from healthy human subjects were expose to either LASV or ML29 in order to identify early cellular responses that could be attributed to the difference in virulence between both viruses. Differential expression of interferon-related genes as well as coagulation-related genes could lead to an explanation for Lassa fever pathogenesis and lead to protective treatments for Lassa fever disease.

2013-11-05 | GSE41300 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data